The 2023 edition of the RNA Editing Summit focused on optimizing RNA editing technology to safely deliver novel payloads, enhancing potency and durability to achieve clinical validation in patients faster. This presentation details the ongoing effort led by ProQR to put in place effective strategies to increase RNA editing yields of ADARs using chemical modifications and oligonucleotide design. The potential of the Axiomer platform in multiple organs, as well as its applicability for the treatment of liver-originated disorders, including data from preclinical models are also included.
Presented at the RNA Editing Summit on July 12, 2023 by Lenka Van Sint Fiet - ProQR Therapeutics
This virtual event on March 29, 2023 featured presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the initial pipeline targets, and provided guidance on the advancement of programs toward the clinic. ProQR also reported its 2022 year-end financials and the extension of its cash runway guidance.
The presentation reviews EONs structure activity, the potential of the Axiomer platform as well as its applicability for the treatment of liver originated disorders. Presented at TIDES USA on May 9, 2023 by Gerard Platenburg - ProQR Therapeutics.